# Surgery and Microbiology

Tim Blackmore

Infectious Diseases Physician and Microbiologist

Wellington

# General surgery and my practice

- Wound microbiology
- Surgical site infection prevention
- Wound care
- Can the sun go down on undrained pus?
- Approach to difficult inoperable collections

### Wound micro

CLINICAL MICROBIOLOGY REVIEWS, Apr. 2001, p. 244–269 0893-8512/01/\$04.00+0 DOI: 10.1128/CMR.14.2.244–269.2001 Copyright © 2001, American Society for Microbiology. All Rights Reserved.

### Wound Microbiology and Associated Approaches to Wound Management

P. G. BOWLER, 1\* B. I. DUERDEN, 2,3 AND D. G. ARMSTRONG 4,5

- Poor clinical indications
  - Provided on form
  - Amongst team, swabs often taken by nurses at dressing changes
  - Sometimes from under VAC
- Difficult to standardise work up in lab
  - S. aureus and S. pyogenes
  - Pseudomonas and anaerobes.
  - Others
- Antibiotics vs wound care

"Consequently, to minimize the opportunity for wound infection and exclude microorganisms as a factor in delayed healing in noninfected wounds, a multidisciplinary approach to wound management, involving a continuous dialogue between laboratory and clinical staff, is vital"

DOB : 14/04/47 Sex: Female Phone : 02041625972(M) 2992418(H) Ethnicity: NZ European Eligible for Publicly funded services?: Yes Patient Opt off Laboratory Record?: No Requester : DR EDWARDS Andrew (13ARKY) Address : Paraparaumu Medical Centre Paraparaumu Priority: Routine Pregnant: No Fasting: No Patient Information: Clinical details: Testing requested: Wound Culture . Does the wound/ulcer have clinical signs of infection? Yes Surgical wound Yes Site sample taken from distal end wound site R) groin · Current or planned antibiotic treatment: Not given







Priority: Routine
Fasting: No
Patient Information :
Clinical details:

#### Testing requested:

#### **Wound Culture**

Does the wound/ulcer have clinical signs of infection?

Yes

Suspicion of MRSA

Yes

· Wound contamination e.g. soil, water, foreign body (specify in clinical details) Yes

Site sample taken from

left shin

· Current or planned antibiotic treatment:

Flucioxacillin

Specimens to be collected (Tube, source)

Purple Swab (Bacterial Transwab), Wound



# Peg tube inflamed site



# The problems with reporting

- Naming an micro-organism often leads to prescribing
- The person signing off the result is often not the person seeing the wound
- Lab staff vary a lot in their assessment of "mixed flora" vs "predominant growth"
- In the end wound microbiology is not very useful
- Planning to shift to only reporting resistant bacteria
- Amoxi-clav or cephalexin and metronidazole



### Infection Prevention





#### SCIENTIFIC REVIEW

Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018

Ongoing debate about oral antibiotics and bowel prep

Recommendation grade:

Intravenous antibiotic prophylaxis: Strong

Oral antibiotic decontamination: Weak

Chlorhexidine-alcohol-based skin preparation: Strong

Advanced measures for skin decontamination: Weak

Patients undergoing resections receiving MBP: Oral and

intravenous prophylaxis: Weak



# Reduction of Surgical Site Infections after Implementation of a Bundle of Care

Rogier M. P. H. Crolla<sup>1</sup>, Lijckle van der Laan<sup>1</sup>, Eelco J. Veen<sup>1</sup>, Yvonne Hendriks<sup>2</sup>, Caroline van Schendel<sup>3</sup>, Jan Kluytmans<sup>2,4</sup>\*


1 Department of surgery, Amphia Hospital, Breda, The Netherlands, 2 Laboratory for Microbiology and Infection Control, Amphia Hospital, Breda, The Netherlands, 3 Operating Theatre, Amphia Hospital, Breda, The Netherlands, 4 Department of Medical Microbiology and Infection Control, VU University Medical Center, Amsterdam, The Netherlands

### • Elements of the bundle:

- perioperative antibiotic prophylaxis,
- hair removal before surgery,
- perioperative normothermia
- discipline in the operating room
  - Measured by number of door openings
    - reducing changes of the team for coffee breaks,
    - making sure all equipment was present before the surgical procedure started
    - not entering the operating room for social talks during the surgical procedure

## Preventing CS wound infections

- Collection of swab surrogate for superficial infection
- Growth of *S. aureus* associated with infection
- Attention to wound closure
- Low clipping
- Dry skin when dressing applied
- Attention paid to dressing application
- Leave dressing undisturbed for as long as possible



Can the sun be allowed to set on undrained pus?

# Multicentre study of non-surgical management of diverticulitis with abscess formation

*B*7*S* 2019; **106**: 458–466

D. P. V. Lambrichts<sup>1,4</sup>, H. E. Bolkenstein<sup>6</sup>, D. C. H. E. van der Does<sup>1</sup>, D. Dieleman<sup>1</sup>, R. M. P. H. Crollo<sup>7</sup>, I. W. T. Dekker<sup>8</sup>, P. van Duiivendiik<sup>9</sup>, M. F. Cerbarde<sup>5</sup>, S. W. Nienbuiic<sup>10</sup>


A V		Total cohort (n = 447)				Hinchey Ib (n = 215)			Hinchey II* (n = 232)		
	Total (n = 447)	No PCD (n = 332)	PCD (n = 115)	P‡	No PCD (n = 197)	PCD (n = 18)	P	No PCD (n = 135)	PCD (n = 97)	P‡	
Short-term outcomes											
Treatment failure	120 (26-8)	79 (23.8)	41 (35.7)	0.013	44 (22-3)	6 (33)	0.359§	35 (25-9)	35 (36)	0.149	
Complications†	25 (5.6)	13 (3.9)	12 (10-4)	0.009	8 (4-2)	0 (0)	0.908§	5 (3.7)	12 (12)	0.032§	
Clinical deterioration/ disease progression	95 (21.3)	59 (17-8)	36 (31.3)	0.002	30 (15-2)	6 (33)	0·091§	29 (21-5)	30 (31)	0-147	
Readmission	71 (15.9)	49 (14-8)	22 (19-1)	0.253	27 (13-7)	5 (28)	0·178§	22 (16-3)	17 (18)	0.714	
Persistent diverticulitis	63 (14-1)	42 (12.7)	21 (18-3)	0.130	23 (11.7)	5 (28)	0·100§	19 (14-1)	16 (16)	0.583	
Emergency surgery (sigmoid resection)	40 (8-9)	24 (7-2)	16 (13-9)	0.030	10 (5-1)	1 (6)	0-693§	14 (10-4)	15 (15)	0.117	
Death	5 (1.1)	3 (0.9)	2 (1.7)	0.607§	3 (1.5)	0 (0)	1.000§	0 (0)	2 (2)	0.332§	
Long-term outcomes											
Complications†	74 (16-6)	46 (13.9)	28 (24-3)	0.009§	25 (12-7)	7 (39)	0.016§	21 (15.6)	21 (22)	0.245	
Overall recurrence	122 (27-3)	93 (28-0)	29 (25.2)	0.474¶	54 (27-4)	7 (39)	0.623¶	39 (28-9)	22 (23)	0.349¶	
Sigmoid resection	124 (27-7)	87 (26-2)	37 (32-2)	0.07¶	57 (28-9)	6 (33)	0.474¶	30 (22-2)	31 (32)	0.046¶	
Death	28 (6-3)	16 (4.8)	12 (10-4)	0.048¶	8 (4-1)	2 (11)	0.263¶	8 (5.9)	10 (10)	0.270¶	

# 46 yr Maori man

Extensive tophaceous gout
Long term prednisone
Perforated sigmoid colon July
Resected with colostomy and pelvic drain
Pelvic collection







25 July

15 Aug

1								
					URINE	CSF / ASPIRATE		
Haematology	Biochemistry			Urine Type	ag Urine 24h	Micro		
☐ CBC	Blood Gas - Inspired O2:				ag Urine □ 24ni n/Out CSU □ Oth			
MUST STATE	- Arterial/Venous -		Micró	Monteso Pon				
ANTICOAG STATUS	☐ Electrolytes (Na/K)		☐ HbA1c	Culture / Sensitivity		Haematology		
☐ INR ☐ On Warfarin	☐ Creatinine		Lipids Random	Cytology	insidercy	CSF Cytospin		
☐ Coag Screen ☐ On Heparin	☐ Ca/Phos/Alb		☐ TSH	Urine Cytol	logy	Biochemistry		
☐ APTT ☐ On Dabigatran	☐ Magneslum		☐ Ferritin	Biochemistry		☐ Protein / Glucose		
D-Dimer On Clexane	Uric Acid		☐ Iron Studies	Random		Cytology		
On Other	Urea		☐ LDH	Creatinine		CSF Cytology		
	☐ Troponin T		☐ B12	Creatinine	Clearance*			
	LFT (ALT, ALP, BIL, T	P & ALB	) 🗌 Folate	Drugs of Al	buse Screen	MDRO Screen		
☐ Haemolytic Screen	Lipase		Protein Electrophoresis	*Serum san	nple also required	☐ MRSA		
1	Osmolality		☐ Immunoglobulins	☐ Osmolality	☐ Total Protein	CRE		
<b>_</b>	CRP	Thera	eutic Drug Monitoring	Na/K	* Microalbumin	□ ESBL		
	□HCG	Drugs:		☐ Ca/Mg'	☐ 5HIAA ¹	□ VRE		
	□PSA	Dose:		☐ PO4	Catecholamine	s Sample Type:		
	Chusese Easting		e Date & Time:	Protein: Creat Ratio		Sample types		
	Glucose Random		e Date & Hime:	# Acid Urine	Container Required			
Antenatal Screening	Imn	Immunology / Serology			Microbiology			
First Visit	☐ Hep A		Mycoplasma	☐ Blood Culture Site:		Faeces		
(Includes CBC, HbA1c, RBC Antibody Screen, Blood Group,	☐ Hep B – Diagnosis (HBsAg)		☐ ANA			Gastro PCR Parasites		
Hepatitis B, Rubella, Syphillis)	Hep B – Immunity (HBsAb)		Complement C3/C4	Swab Site:		C. difficile + CRE * travel history required		
☐ Antenatal + HIV	☐ Hep B Core Total Ab	S	☐ Thyroid TPO Abs	☐ Tissue Site:		* travel history required		
(Supply 1 x Yellow, 2 x Mauve & 1 x Pink)	☐ Hep C Abs		Rheumatoid Abs	Sputum Type:		Chlamydia/Gonorrhoea PCI		
	☐ HIV		Coeliac Screen	I - ' '		Trichomonas		
Subsequent Visit (Includes CBC, RBC Antibodies -	Syphilis		Cardiolipin Abs	_ other _	ANATOMIC PA	_		
Supply 1 x Mauve & 1 x Pink)	Rubella Immunity		Lupus Screen	Histology	ANATOMICE	Cytology		
☐ Glucose Challenge	CMV Abs		☐ DNA Abs	Site:		□ Cytology		
(Supply 1 x Grey)	☐ CMV PCR		ENA Abs	Site.				
Recto / Vag Swab for GBS	☐ EBV Abs		ANCA	I				
	Strep Abs		Lymph Subsets	1				
	Toxoplasma		DATORY LIGE ONLY	4				
SECTION FOR CLINICA								
1			for 25/7.					
	k & nd	stor	~ ~ / F.		- Samples for 55182	00		
			A					
		Proc. at :WEL (Wellington Spec Rec) Proc. : 93/99/2922						
		_	Proc. by : ematth 21:37					
Date Requested: 3/8/22	Time Taken:		Date Taken: -	2/6/22	Taken By:	016		
0(8/20	· . ·			3/8/22		y		

```
Aspirates

ASPIRATES

SITE

ASPIRATE: LAPAROTOMY SIGMOID RESECTION & END STOMA

GRAM STAIN

Large numbers of leucocytes seen.

Mixed flora: no predominant morphotype

CULTURE

Heavy growth of mixed skin and enteric flora

Validated by WGM, MLSci
```

MDRO screens on faeces negative

- Treated with ceftriaxone and metronidazole initially
- Stepped down to oral amoxicillin-clavulanate

### Cascade of antibiotic choices

- Flucloxacillin or cephazolin superficial infection
  - Beware MRSA in Pasifika, Maori, some Asian populations
- Ceftriaxone +metronidazole or amoxy-clav mixed or deep infections
  - Boost AC with amoxicillin unless < 70kg</li>
  - Beware ESBL, particularly in Asian populations
  - ampC producers eg Serratia, Enterobacter, Kleb aerogenes
- Step up to Meropenem
- Pip-tazo only for niche infections now

# Antibiotic gaps/drivers

- Ceftriaxone
  - Some anaerobes, MRSA, enterococcus, pseudomonas, ampC producers, candida
- Ceftazidime
  - Same as ceftriaxone, but covers pseudomonas
- Meropenem
  - MRSA, enterococcus, candida

# My approach to complicated intra abdominal infections

- Screen for MDRO/review old microbiology particularly if frequent hospital attender
- Keep narrow for as long as possible
- Long acting antibiotics to minimise nursing and patient disruption
- Step up and down with one change at a time
  - Amoxi-clav or ceftriaxone and metronidazole
    - Cefepime
      - Meropenem
        - Either add amoxicillin or fluconazole

# My approach continued

- Very rare for inpatients to become septic so usually safe to stop antibiotics but often need to restart
- Decide on marker of infection for that patient
  - CRP
  - Fever
  - General wellbeing
- Check imaging/drainage before assuming antibiotic failure
- Beware C. diff
- Work with surgeon and patient to own antibiotic choices and share the fear